tbuckley/cabot-search huggingface dataset:
Feasibility of lay cancer patient navigation in an academic medical center on unmet needs of cancer patients.
Authors: William Allen Wood, Jean B Sellers, Thomas C. Shea, Deborah Mayer
Journal: Journal of Clinical Oncology (2017)

87 Background: Lay cancer patient navigators (LCPN) are volunteers from the community who assist cancer patients in overcoming barriers to receiving quality cancer care. LCPN can address issues such as. financial burden and psychosocial distress, and can reduce disparities in access to resources. There is little data regarding LCPN within academic medical centers. Methods: In 2013, 24 breast cancer patients at our center were surveyed to determine unmet needs. 82% reported feeling alone and 55% reported lack of awareness about available patient resources. These data supported the development of an LCPN program, in January 2015. Volunteers were provided with comprehensive training that focused on supportive communication, identification of barriers to care, and provision of available cancer resources to address unmet patient needs. Volunteers were integrated within clinical workflows to identify and interact with patients felt to potentially benefit from LCPN. Results: A total of 30 volunteer lay patient navigators were trained between January 2015 – June 2016. Of the 30, 14 elected to staff a weekly disease oriented clinic volunteering 3-4 hours per week. There have been 1,034 patient encounters with 484 encounters in new patients and 550 in repeat patients through June 2016. LCPN completed an encounter form after each patient visit. As a result of these encounters, referrals were provided to the following resources: patient and family resource center (74% ); community resource information (30%); financial counseling (27%); and social work (25%). LCPN report that they feel adequately trained to provide information and meet needs of cancer patients during these visits. Conclusions: We have developed an infrastructure to support an LCPN program within our academic medical center, and have found that this infrastructure facilitates provision of information to cancer patients that addresses their unmet needs. The model is cost-effective and requires few internal resources other than training and ongoing supervision. Future steps will include development of specific interventions to enhance the dissemination of this model throughout North Carolina.
Novel IHC reagents targeted by gene expression data predict recurrence in a retrospective breast cancer cohort at the Comprehensive Cancer Institute of Huntsville (CCIH)
Authors: D. T. Ross, B. Z. Ring, R. S. Seitz, R. Beck, S. Chang, Y. Wang, W. O. Shasteen, F. A. Honkanen, R. J. Gaultieri, N. C. Estopinal
Journal: Journal of Clinical Oncology (2004)

9612 Background: Recent gene expression studies have identified novel classes of breast cancer including a basal/myoepithelial class and a subclass of estrogen receptor-expressing patients which have poor outcomes. It remains unclear how many genes or proteins will need to be measured in order to develop diagnostic tools for patient stratification. Methods: Several hundred affinity-purified anti-peptide antisera were generated to targets chosen on the basis of gene expression data. A selected panel of 24 were tested on tissue arrays which contained 422 diagnostic paraffin blocks from breast cancer patients diagnosed at CCIH from 1989 to 2000 (mean follow-up of 65 months). Results: A panel of only four antibodies had a sensitivity of 57% and specificity of 73% (HR=3.0 p<0.01) for identifying patients who recurred. The prognostic values of these markers were independent of ER, lymph node status, stage, grade, and each other as assessed by a Cox multivariate proportional hazard model. Included in the panel were antisera directed at a predicted “Basal” target, BPAG1 (p<0.01), at a predicted “Luminal B” target, SLC7A5 (p<0.01), at a novel cadherin-related protein (p=0.01), and at an antisera directed at a putative methyltransferase expressed in a cell cycle dependent manner (p<0.01). Furthermore, the novel cadherin-related protein and the putative cell cycle regulated methyltransferase showed significant correlations with survival. Conclusions: Novel subclasses of breast cancer associated with poor outcome identified by gene expression studies can be distinguished by a panel of novel IHC antisera. These reagents should prove useful for patient stratification in early stage breast cancer patients. The expanded panel, which distinguishes broader biologic diversity in breast cancer, should prove useful for retrospective and prospective studies designed to identify responder populations in adjuvant clinical trials. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Applied Genomics, Inc. Applied Genomics, Inc. Applied Genomics, Inc.
Routine physical function assessment through a Branching Logic Electronic Symptom Survey (BLESS) vs. the 32-combined item HAQ-DI + WHODAS (HW) survey: A quality improvement controlled trial.
Authors: Emily Tam, Judy Chen, Qihuang Zhang, Dennis Zheng, Vivian Tam, Yuchen Li, Tiffany Tse, M Catherine Brown, Wei Xu, Doris Howell, Geoffrey Liu, Elizabeth Hall
Journal: Journal of Clinical Oncology (2017)

136 Background: Routine outpatient physical function assessment can improve quality of care by prioritizing supports for specific patients. However, conventional research surveys including the 32-combined item HAQ-DI + WHODAS (HW) may be burdensome to patients. To streamline this process, we have developed BLESS, an electronic patient reported outcomes software program that utilizes PRO-ECOG and EQ-5D-3L items to screen for physical dysfunction symptoms, with follow-up questions from HW; BLESS has been demonstrated to have high sensitivity and specificity for the complete HW survey. We compared completion times and patient acceptability of BLESS vs. HW. Methods: Adult oncology outpatients of all stages at Princess Margaret Cancer Centre were allocated prospectively and alternately to receive either BLESS or HW on touchscreen tablets. Completion times were recorded and a patient acceptability survey was administered. Results: Of 225 patients analyzed from breast (19%), GI (22%), GU (12%), gynecology (16%), head/neck (12%), skin (6%) and thoracic (13%) cancer clinics, 118 (52%) patients completed BLESS and 107 (47%) completed HW. Median age was 61 (range: 18-97) years; 60% were female, 68% were Caucasian, 44% were stage IV, and 57% were treated with a curative intent. There were no statistically significant differences in demographic and clinical characteristics between the arms analyzed. Median EQ-5D-3L utility was 0.83 (0.28-1.00), median HAQ-DI was 0.13 (0-3.00) and median WHODAS was 8.3% (0-83.3%). Compared to HW, BLESS resulted in a median completion time reduction of 3.9 minutes (32% decrease; p &lt; 0.001). Although most patients in both arms did not find the survey time-consuming nor caused the clinic visit to be more difficult, a greater proportion of BLESS patients held a stronger conviction in their answers (p = 0.02 for both comparisons). Conclusions: In comparison to traditional research tools of HW for assessing physical function,BLESS was associated with shorter administration times and improved patient acceptability, rendering BLESS more suitable for routine clinical use.
Body Iron Stores and the Gender Gap in Risk of Incident Myocardial Infarction
Authors: Luca Mascitelli, Mark R. Goldstein
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Use of a secure mobile application to inform clinicians on adverse event management and drug-drug interactions for ribociclib: Experiences with CT scholar in ribociclib clinical trials.
Authors: Tania Small, Najla Bugazia, Brigette Nezami, Michael Vinegra, Alberto Fernandez, Shyeilla V. Dhuria, Jaclyn Feeley, Lance Burroughs
Journal: Journal of Clinical Oncology (2017)

134 Background: Understanding and gaining familiarity with the adverse event (AE) and drug-drug interaction (DDI) potential of novel agents can be challenging, cumbersome, and time consuming for clinicians. A comprehensive and secure AE management/DDI mobile application (CT Scholar [Novartis Pharmaceuticals Corp]) was developed to ease the management of clinical trial participants with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer receiving ribociclib. Methods: CT Scholar was designed specifically for the ribociclib clinical program to provide easy access to information on AE and DDI management. The AE management module characterizes and quickly informs drug-specific AE management based on protocol guidelines and supportive care guidance. The DDI module includes a database of &gt; 100 drugs searchable by both trade and generic name. Number of application visits, unique users, and screen views were monitored from Jan to Sept 2016. Results: There were 1055 visits to CT Scholar (117/month) by 145 unique users (28/month), with 5764 screen views (640/month) and 5.5 screens viewed/visit. Among the most-viewed modules were hematologic AE management (1132 views), gastrointestinal AE management (771), and DDI (734). Diarrhea, neutropenia, and nausea were the most viewed submodules (308, 230, and 205 views, respectively). The information on CT Scholar was consistently shown to be accessed more quickly than information obtained from printed clinical protocols. No patients discontinued from the ribociclib studies due to AEs following the introduction of CT Scholar. Conclusions: CT Scholar was widely used by clinicians, and it responded to their needs by providing essential information, especially on prevalent AEs, which could be easily updated and rapidly accessed. Additionally, CT Scholar provides a platform showing how technology can assist clinicians and patients in managing care during a trial, which can inform the development of future supportive materials.
Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program.
Authors: Carolina Ortiz, Guillem Argilés, Elena Élez, Judit Matito, Leire Mendizabal, Deborah Lo Giacco, Francesco M Mancuso, Enrique Sanz-Garcia, Teresa Macarulla, Maria Alsina, Jaume Capdevila, Tamara Saurí, Analia Azaro, Cristina Cruz, Cinta Hierro, Santiago Ramon y Cajal, Paolo Nuciforo, Jordi Rodón, Josep Tabernero, Ana Vivancos
Journal: Journal of Clinical Oncology (2015)

3598 Background: Molecular screening and biomarker enrichment strategies in mCRC trials may impact patient (pt)´s outcome. The introduction of NGS technologies in clinical investigation may enhance pt inclusion through the discovery of a wider set of mutations (mt) in oncogenes and tumor suppressor genes. Methods: From March/2012 to December/2014 411 pts with chemorefractory mCRC underwent genetic tumor profiling as part of the molecular enhancement strategy in our early drug development program. Base extension chemistry followed by mass detection (MassARRAY, Sequenom) (SQ) was used including 268 frequent hotspots in 25 oncogenes with a sensitivity of 10% of mutant alleles. Since June/2014, Amplicon sequencing (NGS) was implemented assessing mt in 59 oncogenes and tumor suppressors with a sensitivity of 3% mutant alleles. Results: From March/2012 to Jun/2014 324 pts were screened using SQ, 261 mt were detected: 0.80 mt per patient. A total of 117 pts (36%) resulted wild-type (wt) after the test. Frequency of mt were: 48.77% KRAS, 16.67% PI3KCA, 7.41% NRAS, 7.41% BRAF, along with minor events: 2 mt in AKT1 and 1 mt in PDGFRA, GNAS and ERBB2 allowing a total of 89 inclusions on matched targeted therapies (27.47% inclusion rate per total samples). From Jun/2014 to Dec/2014 78 pts were screened with NGS, 5 pts (6%) were wt. A total of 160 mt were detected (1.83 mt per patient): 44.83% KRAS, 4.6% NRAS, 51.72% TP53, 43.68% APC, 5.75% BRAF, 5% PI3KCA, 4.6% SMAD4, 3.45% PTEN and 1mt in GNAS, AKT2, MET, STK11, FBXW7, JAK3, FGFR1, NOTCH1, MSH6, RNF43, RET and NF2 providing 21 inclusions to treatment with targeted therapy (26.4% inclusions per total samples). Conclusions: Our results show that NGS techniques allow the identification of a wider spectrum of mts per patient compared to prior generation genomic tests, although this has failed to be translated yet into higher inclusion rates in clinical trials with targeted agents. An enhanced discovery of mutations in tumor suppressor genes, thus far out of therapeutic reach and other factors like recent implementation of NGS and the increasing search for more specific molecular populations can contribute to this fact.
Comparing patients with breast and prostate cancer in terms of their mental health comorbidities as predictors of cost and utilization.
Authors: Harry Burke, C. Allison Russo, Laura Hopkins, Diana D Jeffery
Journal: Journal of Clinical Oncology (2017)

18 Background: We compared the role played by mental health comorbidities in the health care cost and utilization of non-elderly patients with breast and prostate cancer. Methods: The Military Health System affords its beneficiaries equal access to medical care. We performed a cross-sectional analysis using administrative data of all 9.5 million beneficiaries, ages 18-64, with direct care and a primary diagnosis of either invasive breast or prostate cancer during FY2007–FY2014. We used regression models to identify predictors of cost and utilization, including sociodemographic variables, system of care, treatment modalities, chronic disease comorbidities, and mental health comorbidities. Results: On average,annuallythere were 23,800 and 13,300 patients with breast or prostate cancer, respectively. More comorbid depression (16.8%) or anxiety (14.2%) occurred among breast cancer patients than prostate cancer patients (6.9%, 6.7%). Annual cost per patient (inc. pharmacy) was significantly higher for breast cancer ($16,287 vs. $11,069, p &lt; 0.001). The strongest predictors of annual breast cancer costs were (in order from highest predictive value) chemotherapy, surgery, and mood or adjustment disorder (p &lt; 0.0001); the strongest predictors for prostate costs were chemotherapy, radiation therapy, surgery, and mood or adjustment disorder (p &lt; 0.0001). Mood and adjustment disorders were strong predictors of the annual number of ambulatory visits, hospital admissions, and bed days for both breast and prostate cancer (p &lt; 0.0001). Conclusions: Mental health comorbidities play a significant role in health care costs and utilization of non-elderly adults who are breast and prostate cancer patients. An unexpected finding was that, although different in frequency, mental health comorbidities were important predictors of cost and utilization for both patients with breast and prostate cancer. For both breast and prostate cancer, routine screening and treatment for mental health disorders should be part of quality cancer care.
Prime Time for Shared Decision Making
Authors: Erica S. Spatz, Harlan M. Krumholz, Benjamin W. Moulton
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Authors: Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma, James Allison, Funda Meric-Bernstam, David S. Hong
Journal: Journal for ImmunoTherapy of Cancer (2017)

<h3>Background</h3> Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imatinib combined with ipilimumab would be tolerable and may synergize in patients with advanced cancer. <h3>Methods</h3> Primary objective of the dose-escalation study (3 + 3 design) was to establish the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included evaluation of antitumor activity of the combination based on KIT mutation status and the capacity of tumor-associated immune biomarkers to predict response. <h3>Results</h3> The primary objective to establish the maximum tolerated dose (MTD) was achieved, and the recommended phase II doses are ipilimumab at 3&nbsp;mg/kg every 3&nbsp;weeks and imatinib 400&nbsp;mg twice daily. Of the 35 patients treated in the escalation and GIST expansion, none experienced dose-limiting toxicities. The most common grade 1/2–related adverse events (AEs) were fatigue (66%), nausea (57%), anorexia, vomiting (each 31%), edema (29%), and anemia, diarrhea, and rash (each 23%). Grade 3 AEs occurred in 6 patients (17%) and included fatigue, anemia, fever, rash, and vomiting. There were no grade 4 AEs. In general, the combination was well tolerated. Among all patients, 2 responses were seen: 1 partial response (GIST) and 1 partial response (melanoma). Stable disease was seen in 6 patients lasting an average of 6&nbsp;months. The melanoma responder was KIT mutated and the GIST responder was wild-type. <h3>Conclusions</h3> Our findings suggest that this combination of a targeted agent with checkpoint blockade is safe across multiple tumor types. Low activity with no clear signal for synergy was observed in escalation or GIST expansion cohorts. Assessment of antitumor activity of this combination in the KIT-mutant melanoma population is being evaluated. <h3>Trial registration</h3> Clinicaltrials.gov NCT01738139, registered 28 November 2012.
Prognostic factors for survival with primary site preservation (SPP) in patients with resectable locally advanced squamous cell carcinoma (R-LA-SCC) of larynx and hypopharynx treated with induction chemotherapy (IC) followed by radiotherapy (RT) in an organ preservation setting
Authors: M. E. Vega-Villegas, F. Rivera, A. García-Castaño, M. López-Brea, A. López-Muñoz, A. De-Juan, A. Collado, A. Del-Valle, J. Rama, J. Sanz-Ortiz
Journal: Journal of Clinical Oncology (2004)

5547
The inhibition effects of a traditional Chinese medicine on glioblastoma.
Authors: Hui Huang, Guijuan Yue, Yuying Qu, Qiuling Wang, Na Li, Jiansheng Li
Journal: Journal of Clinical Oncology (2014)

e13001 Background: Jinlong capsules is a kind of traditional compound Chinese medicine, of which the mechanism of action is complex. This study was conducted to explore its inhibition effect on glioblastoma and the mechanisms, combing genomics, system biology and network pharmacology methods. Methods: The glioblastoma in situ nude mice models with red flurescence protein marked were established and administrated with vehicle, Jinlong capsules (0.75 g·kg-1, 1.5 g·kg-1), and temozolomide capsule (0.096 g·kg-1) respectively. Tumor size and weight were monitored in real time. 28 days later, mice were killed and the intracranial tumors were weighed, with the gene expression profiles detected. The genome results were analysed by system biology and network pharmacology methods. Firstly, differentially expressed genes were identified. Then, these differentially expressed genes were subjected to interactome analysis, generating a set of topologically significant genes. Next, concurrent pathway enrichment analysis on key pathways, processes and other functional units of both differentially expressed genes and topologically significant genes is performed. All the above analysis assisted to build a condition-specific network (called causal network), to model molecular events. Results: Jinlong capsules and temozolomide capsule all showed notable inhibition effects on tumor growth (vs. vehicle: P < 0.05). 18 up-regulated genes and 22 down-regulated genes have been identified between Jinlong capsules-treated sample and vehicle sample with fold change of over 2. The connection analysis identified 106 topologically significant genes. A causal network model was build, of which the main feature is stimulation of neural cell specific genes, which regulate normal cell physiology–mostly developmental processes and apoptosis. The other important feature is inhibition of genes-markers of interferon response, suggesting inhibition of its signaling, followed by de-activation of inflammatory response. Conclusions: Jinlong capsules can suppress the glioblastoma growth of nude mice. The key features of its mechanisms are down-regulation of interferon signaling and stimulation of neural cell–specific physiology.